← Leaderboards
Scott R Barnum
University Of Alabama At Birmingham
$3,363,757
Attributed
$4,337,982
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $659.3K · FY2005–14$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$4,337,982 · 8
By mechanism
R01$3,151,513 · 3
R21$803,919 · 2
P01$226,133 · 1
R03$146,417 · 1
R13$10,000 · 1
Top collaborators
- Rakesh Pravinchandra Patel4 shared
- Jordan Allan Weinberg4 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Jianmei Wu Leavenworth$3,731,030
- Jordan Allan Weinberg$487,113
- Tyler T Wright$74,219
- Narayana Vl Sthanam$5,250,626
- Theresa N Ramos$24,498
Others in their field
Top investigators on “Complement”
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$128,874,888
- Wafaa M. El-Sadr · Columbia University Health Sciences$101,800,876
- Myron S Cohen · Family Health International$101,800,876
- Steve Riordan · Westat, Inc.$94,143,268
- David R. Weir · University Of Michigan At Ann Arbor$93,718,087
- Stuart L Schreiber · Harvard University (Medical School)$88,512,978
Research focus
ComplementComplement ActivationInflammationBasePublic Health RelevanceMediatingPathway InteractionsAttenuatedGene ExpressionPathologyInflammatoryMultiple SclerosisImmunocytochemistryImmune ResponseTissuesGlial Fibrillary Acidic ProteinSignal TransductionExperimental Allergic EncephalomyelitisLaboratory MouseEventComplement PathwayDepositionAntibodiesAnimal Model
Grant awards (23)
The Role of the Terminal Complement Pathway in ALS$181,294
R21 · FY2014 · NS · contact PI
The Role of the Terminal Complement Pathway in ALS$219,750
R21 · FY2013 · NS · contact PI
RBC age and potentiation of transfusion related pathology in trauma patients$362,588
R01 · FY2012 · HL
RBC age and potentiation of transfusion related pathology in trauma patients$366,250
R01 · FY2011 · HL
Complement-based Therapeutics in Demyelinating Disease$183,125
R21 · FY2011 · NS · contact PI
RBC age and potentiation of transfusion related pathology in trauma patients$366,250
R01 · FY2010 · HL
Complement-based Therapeutics in Demyelinating Disease$219,750
R21 · FY2010 · NS · contact PI
Generation of complement C9 conditional knockout mice and anti-C9 mAbs$73,250
R03 · FY2010 · AI · contact PI
RBC age and potentiation of transfusion related pathology in trauma patients$366,250
R01 · FY2009 · HL
Generation of complement C9 conditional knockout mice and anti-C9 mAbs$73,167
R03 · FY2009 · AI · contact PI
The Role of C3 and C3 receptors in Experimental Autoimmune Encephalomyelitis$299,397
R01 · FY2007 · NS · contact PI
The Role of C3 and C3 receptors in EAE$261,947
R01 · FY2006 · NS · contact PI
The Role of C3 and C3 receptors in EAE$40,000
R01 · FY2006 · NS · contact PI
The Role of C3 and C3 receptors in EAE$23,516
R01 · FY2006 · NS · contact PI
The Role of C3 and C3 receptors in EAE$268,250
R01 · FY2005 · NS
Conference on Central Nervous System Inflammation$10,000
R13 · FY2005 · NS
The Role of C3 and C3 receptors in EAE$268,250
R01 · FY2004 · NS
The Role of C3 and C3 receptors in EAE$10,875
R01 · FY2004 · NS
EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS--INHIBITION OF C$160,612
R01 · FY2002 · NS
EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS--INHIBITION OF C$155,934
R01 · FY2001 · NS
C51, IL-8 AND FMLP RECEPTOR EXPRESSION BY GLIAL CELLS$226,133
P01 · FY2000 · NS
EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS--INHIBITION OF C$151,394
R01 · FY2000 · NS
EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS--INHIBITION OF C$50,000
R01 · FY2000 · NS